Study	study	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
role	role	O	O	O	O
of	of	O	O	O	O
vitamin	vitamin	CHEMICALS	O	OTHERS	I
B12	b12	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
folinic	folinic	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
supplementation	supplementation	O	O	O	O
in	in	O	O	O	O
preventing	preventing	O	O	O	O
hematologic	hematologic	O	O	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
of	of	O	O	O	O
zidovudine	zidovudine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
prospective	prospective	O	O	O	O
,	,	O	O	O	O
randomized	randomized	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
conducted	conducted	O	O	O	O
to	to	O	O	O	O
evaluate	evaluate	O	O	O	O
the	the	O	O	O	O
role	role	O	O	O	O
of	of	O	O	O	O
vitamin	vitamin	CHEMICALS	O	OTHERS	I
B12	b12	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
folinic	folinic	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
supplementation	supplementation	O	O	O	O
in	in	O	O	O	O
preventing	preventing	O	O	O	O
zidovudine	zidovudine	CHEMICALS	O	OTHERS	I
(ZDV)-induced	(zdv)-induced	O	O	O	O
bone	bone	O	DISEASE	OTHERS	I
marrow	marrow	O	DISEASE	OTHERS	I
suppression	suppression	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Seventy-five	seventy-five	O	O	O	O
human	human	O	O	OTHERS	I
immunodeficiency	immunodeficiency	O	O	OTHERS	I
virus	virus	O	O	OTHERS	I
(HIV)-infected	(hiv)-infected	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
CD4	cd4	O	O	O	O
+	+	O	O	O	O
cell	cell	O	O	O	O
counts	counts	O	O	O	O
<	<	O	O	O	O
500/mm3	500/mm3	O	O	O	O
were	were	O	O	O	O
randomized	randomized	O	O	O	O
to	to	O	O	O	O
receive	receive	O	O	O	O
either	either	O	O	O	O
ZDV	zdv	O	O	OTHERS	I
(	(	O	O	O	O
500	500	O	O	O	O
mg	mg	O	O	OTHERS	I
daily	daily	O	O	O	O
)	)	O	O	O	O
alone	alone	O	O	O	O
(	(	O	O	O	O
group	group	O	O	O	O
I	i	O	O	O	O
,	,	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
38	38	O	O	O	O
)	)	O	O	O	O
or	or	O	O	O	O
in	in	O	O	O	O
combination	combination	O	O	O	O
with	with	O	O	O	O
folinic	folinic	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
15	15	O	O	O	O
mg	mg	O	O	OTHERS	I
daily	daily	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
intramascular	intramascular	O	O	O	O
vitamin	vitamin	CHEMICALS	O	OTHERS	I
B12	b12	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
1000	1000	O	O	O	O
micrograms	micrograms	O	O	O	O
monthly	monthly	O	O	O	O
)	)	O	O	O	O
(	(	O	O	O	O
group	group	O	O	O	O
II	ii	O	O	O	O
,	,	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
37	37	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Finally	finally	O	O	O	O
,	,	O	O	O	O
15	15	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
excluded	excluded	O	O	O	O
from	from	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
(	(	O	O	O	O
noncompliance	noncompliance	O	O	O	O
14	14	O	O	O	O
,	,	O	O	O	O
death	death	O	DISEASE	OTHERS	I
1	1	O	O	O	O
)	)	O	O	O	O
;	;	O	O	O	O
thus	thus	O	O	O	O
,	,	O	O	O	O
60	60	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
31	31	O	O	O	O
in	in	O	O	O	O
group	group	O	O	O	O
I	i	O	O	O	O
and	and	O	O	O	O
29	29	O	O	O	O
in	in	O	O	O	O
group	group	O	O	O	O
II	ii	O	O	O	O
)	)	O	O	O	O
were	were	O	O	O	O
eligible	eligible	O	O	O	O
for	for	O	O	O	O
analysis	analysis	O	O	O	O
.	.	O	O	O	O

No	no	O	O	O	O
significant	significant	O	O	O	O
differences	differences	O	O	O	O
between	between	O	O	O	O
groups	groups	O	O	O	O
were	were	O	O	O	O
found	found	O	O	O	O
at	at	O	O	O	O
enrollment	enrollment	O	O	O	O
.	.	O	O	O	O

During	during	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
,	,	O	O	O	O
vitamin	vitamin	CHEMICALS	O	OTHERS	I
B12	b12	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
folate	folate	CHEMICALS	O	OTHERS	I
levels	levels	O	O	O	O
were	were	O	O	O	O
significantly	significantly	O	O	O	O
higher	higher	O	O	O	O
in	in	O	O	O	O
group	group	O	O	O	O
II	ii	O	O	O	O
patients	patients	O	O	O	O
;	;	O	O	O	O
however	however	O	O	O	O
,	,	O	O	O	O
no	no	O	O	O	O
differences	differences	O	O	O	O
in	in	O	O	O	O
hemoglobin	hemoglobin	O	O	O	O
,	,	O	O	O	O
hematocrit	hematocrit	O	O	O	O
,	,	O	O	O	O
mean	mean	O	O	O	O
corpuscular	corpuscular	O	O	O	O
volume	volume	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
white-cell	white-cell	O	O	O	O
,	,	O	O	O	O
neutrophil	neutrophil	O	O	O	O
and	and	O	O	O	O
platelet	platelet	O	O	O	O
counts	counts	O	O	O	O
were	were	O	O	O	O
observed	observed	O	O	O	O
between	between	O	O	O	O
groups	groups	O	O	O	O
at	at	O	O	O	O
3	3	O	O	O	O
,	,	O	O	O	O
6	6	O	O	O	O
,	,	O	O	O	O
9	9	O	O	O	O
and	and	O	O	O	O
12	12	O	O	O	O
months	months	O	O	O	O
.	.	O	O	O	O

Severe	severe	O	O	O	O
hematologic	hematologic	O	O	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
(	(	O	O	O	O
neutrophil	neutrophil	O	O	O	O
count	count	O	O	O	O
<	<	O	O	O	O
1000/mm3	1000/mm3	O	O	O	O
and/or	and/or	O	O	O	O
hemoglobin	hemoglobin	O	O	O	O
<	<	O	O	O	O
8	8	O	O	O	O
g/dl	g/dl	O	O	O	O
)	)	O	O	O	O
occurred	occurred	O	O	O	O
in	in	O	O	O	O
4	4	O	O	O	O
patients	patients	O	O	O	O
assigned	assigned	O	O	O	O
to	to	O	O	O	O
group	group	O	O	O	O
I	i	O	O	O	O
and	and	O	O	O	O
7	7	O	O	O	O
assigned	assigned	O	O	O	O
to	to	O	O	O	O
group	group	O	O	O	O
II	ii	O	O	O	O
.	.	O	O	O	O

There	there	O	O	O	O
was	was	O	O	O	O
no	no	O	O	O	O
correlation	correlation	O	O	O	O
between	between	O	O	O	O
vitamin	vitamin	CHEMICALS	O	OTHERS	I
B12	b12	CHEMICALS	O	OTHERS	I
or	or	O	O	O	O
folate	folate	CHEMICALS	O	OTHERS	I
levels	levels	O	O	O	O
and	and	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
myelosuppression	myelosuppression	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Vitamin	vitamin	CHEMICALS	O	OTHERS	I
B12	b12	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
folinic	folinic	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
supplementation	supplementation	O	O	O	O
of	of	O	O	O	O
ZDV	zdv	O	O	OTHERS	I
therapy	therapy	O	O	O	O
does	does	O	O	O	O
not	not	O	O	O	O
seem	seem	O	O	O	O
useful	useful	O	O	O	O
in	in	O	O	O	O
preventing	preventing	O	O	O	O
or	or	O	O	O	O
reducing	reducing	O	O	O	O
ZDV-induced	zdv-induced	O	O	O	O
myelotoxicity	myelotoxicity	O	O	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
overall	overall	O	O	O	O
treated	treated	O	O	O	O
population	population	O	O	O	O
,	,	O	O	O	O
although	although	O	O	O	O
a	a	O	O	O	O
beneficial	beneficial	O	O	O	O
effect	effect	O	O	O	O
in	in	O	O	O	O
certain	certain	O	O	O	O
subgroups	subgroups	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
can	can	O	O	O	O
not	not	O	O	O	O
be	be	O	O	O	O
excluded	excluded	O	O	O	O
.	.	O	O	O	O

